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Helen K. Hayward-Könnecke, MD,‡ Alfred Buck, MD,*
Spyros S. Kollias, MD,§ and Martin W. Huellner, MD*
Purpose: To investigate the diagnostic value of 18F-fluoroethyl-L-tyrosine
(FET) positron emission tomography (PET) in patients with suspected
tumefactive demyelinating disease.
Methods: We retrospectively examined FET-PET and MR imaging of
21 patients (12 female, 9 male) with known demyelinating disease and
newly diagnosed tumefactive lesions. The maximum standardized uptake
value (SUVmax), time activity curves (TAC) and lesion-to-background ratio
(TBR) of these lesions were calculated. The standard of reference consisted
of biopsy and/or follow-up imaging. FET parameters of true neoplastic le-
sions and tumefactive demyelinating lesions were compared using Mann-
Whitney U-test and receiver operating characteristic (ROC) analysis.
Results: Nine patients (42.9%) had neoplastic lesions, 12 patients (57.1%)
had tumefactive demyelinating lesions. TBRmax, SUVmax and TAC were
significantly different between demyelinating lesions and neoplastic lesions:
Tumors had a higher TBRmax (3.53 ± 1.09 vs. 1.48 ± 0.31, respectively;
P < 0.001) and SUVmax (3.95 ± 1.59 vs. 1.86 ± 0.50, respectively;
P < 0.001) than tumefactive demyelinating lesions. The TAC of tumors
was significantly higher compared to tumefactive demyelinating lesions
at all time points (P < 0.05). ROC analysis revealed that a TBRmax threshold
of 2.2 and a SUVmax threshold of 2.5 could reliably differentiate tumor
and tumefactive demyelination (area under the curve, 1.000 and
0.958, respectively).
Conclusion: In patients with demyelinating disease, FET-PET parameters
TBRmax (cut-off 2.2) and SUVmax (cut-off 2.5) are able to distinguish
tumefactive demyelinations from true neoplastic lesions.
Key Words: demyelinating disease, multiple sclerosis, ADEM, Balo,
18F-FET, PET, tyrosine, PET/CT, brain tumors, glioblastoma,
central lymphoma, MR, PET/MR
(Clin Nucl Med 2018;43: e385–e391)
S everal types of inflammatory demyelinating diseases (IDD)mayexhibit tumefactive characteristics, such as the comparatively
rare “classic” tumefactivemultiple sclerosis (TMS), acute disseminated
encephalomyelitis (ADEM, a multifocal demyelinating disease
often seen after an infectious illness), Balo’s concentric disease,
as well as pattern III multiple sclerosis.1,2 Patients with single
tumefactive demyelinating lesions (TDL), being considered a
separate entity on a spectrum between MS and ADEM, occasionally
proceed to multiple sclerosis.1,3–6 For the purpose of our study, the
term tumefactive demyelinating disease (TDD) is used as umbrella
term for all of the aforementioned entities.
TMS is defined as a large (>2 cm) lesion on radiologic imag-
ing, which is often accompanied by edema and mass effect and
shows ring enhancement.1,7,8 However, a recent trial showed that
lesions<2 cmmayexhibit similar imaging characteristics, reflecting the
ambiguity of the definition of TMS lesions.8 So far, no large-scale
epidemiological data is available on TDD.1,7 In older trials, the in-
cidence of TDD was estimated 0.3 cases per 100,000 population
per year, and the prevalence 1–2 per 1000 cases of MS,9–11 with
a slight female predominance. The mean age at TDD onset is be-
tween 30 and 40 years. The incidence of ADEM varies between
0.07 and 0.64 per 100,000 per year. Specific epidemiological data
on Balo’s concentric disease is lacking.12–14
Clinical symptoms of TDD depend on lesion size, location
and mass effect. Lesions are typically found in the white matter of
the frontal and parietal lobes as well as in the corpus callosum.1,6,7
Similar to tumors, TDD may appear as solitary lesion or multiple
lesions, and might exhibit signal characteristics on magnetic reso-
nance (MR) imaging similar to neoplastic brain lesions.1,9,15 Not
only its presentation on diagnostic imaging, but also the clinical
presentation of TDDmight mimic a neoplastic brain lesion, includ-
ing the event of acute life-threatening situations.
In order to achieve a definite diagnosis, stereotactic biopsy
with subsequent histopathological examination is considered stan-
dard of reference. Although severe complications of stereotactic
biopsy, such as major bleeding or infection, are rather uncommon,
the invasive nature of the procedure still exposes the patient to a
certain risk, and is comparably expensive.1
Cases of TDD and synchronous or metachronous brain
tumors have been reported.16–18 Several studies suggested an
association between MS and astrocytoma, oligodendroglioma
and glioblastoma.19–21 However, such possible associations might
be misleading. It is not known if the possible higher rate of neoplas-
tic brain lesions in MS patients is purely incidental due to frequent
follow-up neuroimaging scans (surveillance bias), or if causative
factors are present in patients with demyelinating disease. Such
might be the inflammation in the context of disease itself or its
treatment with immunomodulating drugs, which might promote
the development of brain tumors.22 Moreover, it is not well under-
stood if demyelinating lesions and glial tumors—if associated—
have a different course.22
Positron emission tomography (PET) imaging using the
radiotracer 18F-fluoroethyl-L-tyrosine (FET) was shown useful
in brain lesions, e.g. for the discrimination of low-grade tumors
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and non-neoplastic lesions fromhigh-grade tumors and lymphoma.23–26
FET is taken up selectively into tumor tissue, and accumulates
rather slowly in non-tumoral tissue.27–30 FET-PET as non-invasive
toolwas also shown useful for biopsy guidance, as well as treatment
planning and monitoring.31–34
To date, the available literature on the diagnostic value of
FET-PET in patients with suspected TDD is limited to a single case
report, which showed a benefit of FET-PET for the differentiation of
tumefactive demyelination from neoplastic brain lesions.17 Thus,
the aim of our study was to investigate the diagnostic value of
FET-PET in patients with suspected TDD, particularly for the dis-
crimination of tumefactive demyelinations from true brain tumors.
MATERIALS AND METHODS
This retrospective study was accepted by the local ethics
committee. Our institution uses a general consent form for all retro-
spective studies since 2014. Only patients who signed this consent
form were included. Informed consent was waived for patients
scanned before 2014. Patients with documented refusal of consent
to retrospective studies were not enrolled into our study. The radio-
tracer FET-PET is approved for the work-up of suspected brain
tumors in our country.
Clinical Data
Our hospital serves as a national reference center for the diag-
nosis and treatment of brain tumors.
Patients fulfilling the following criteria were included into
our study: diagnosis of demyelinating disease; newly diagnosed
tumefactive lesion; available MR scan with T1-weighted (T1w)
post-contrast images, fluid-attenuated inversion recovery (FLAIR)-
weighted images and diffusion-weighted images (DWI); FET-PET
scan performed for further characterization of the lesion. As a matter
of fact, this limits our study cohort to patients with equivocal or
inconclusive MR scans. A query in the radiological information
system, using the keywords “multiple sclerosis,” “MS,” “demye-
linating” and “tumefactive” in conjunction with the imaging mo-
dality FET-PET, yielded 25 patients. Of those, four patients were
subsequently not included due to refusal of consent. Clinical and
demographic data are given in Table 1.
Image Analysis
Imaging analysis included the FET-PET scan mentioned
above, and the last MR scan before the FET-PET scan.
MR Imaging
The size and volume of the tumefactive lesion was assessed
on FLAIR-weighted images. The borders of the lesion were charac-
terized on FLAIR-weighted images as well-defined or ill-defined.
Other observed features concerned the presence of contrast en-
hancement on T1w images, the presence of perilesional edema on
T2-weighted (T2w) images, presence of signs of cerebrospinal fluid
(CSF) circulation impairment, presence of restricted diffusion on
DWI and apparent diffusion coefficient (ADC)map. The ADC signal
was subdivided into bright, mixed or dark appearance. Finally, the
time distance between MR exam and FET-PET scan was recorded.
Owing to the retrospective nature of our study, MR exams were
carried out on different MR scanners.
FET-PET Imaging
FET-PETexams were carried out on Discovery VCT scanner
(GE Healthcare, Waukesha WI) or a Discovery 690 Standard
scanner (GE Healthcare). The standard protocol used at our insti-
tution requires an injection of 130 MBq of 18F-FET. The dynamic
FET-PET acquisition started 20 min after tracer injection, using
four 5 min frames, with a total acquisition time of 20 min. Dynamic
and static PET image datasets were reconstructed from raw data.
Emission data was corrected following a standardized procedure
(randoms, dead time, scatter, attenuation). The attenuation-corrected
axial PET datasets were reconstructed assuming a matrix size of
128  128 pixels (voxel spacing: 2.3438  2.3438  3.27). All
FET-PET data analyses were conducted using PMOD®3.7 (PMOD
technologies, Zürich, Switzerland), which allows for a retrospective
co-registration of FET-PET and MR images.
The following FET-PET parameters were assessed: the
maximum standardized uptake value (SUVmax), tumefactive lesion-
to-background ratio (TBRmax) and time activity curve (TAC) pattern.
TBRmax was derived by dividing the SUVmax of the lesion by the
SUVmean of the contralateral normal parietal lobe. As suggested by
Calcagni et al., the slope of the TACwas subdivided into three different
types.24 The first type (so-called “wash-in”) shows an increase of
more than 10% during dynamic acquisition. The second type
(“plateau”) shows a stable curve with less than 10% change over
time. The third type (“wash-out”) shows a decrease of more than
10%. According to Pöpperl et al., the sum of the frame-to-frame
differences (SoD) in SUVmax was calculated using the formula
Σ (ni − ni−1).25
Standard of Reference
All available surgery and/or biopsy results were consid-
ered. If histopathology was not available, clinical and imaging
follow-up was considered. Shrinkage of lesions over time in the
TABLE 1. Demographic Data of Patients
Age
Median ± SD (y) 47.0 ± 14.9
Range (y) 21–72
Gender
Female (n (%)) 12 (57.1)
Male (n (%)) 9 (42.9)
Previously diagnosed demyelinating disease
Primary progressive MS (n (%)) 3 (14.3)
Relapsing-remitting MS (n (%)) 7 (33.3)
TMS (n (%)) 2 (9.5)
Clinically isolated syndrome (n (%)) 5 (23.8)
Balo concentric sclerosis 1 (4.8)
ADEM (n (%)) 3 (14.3)
Reason for referral: suspicion of…
ADEM or brain tumor (n (%)) 3 (14.3)
Balo or brain tumor (n (%)) 1 (4.8)
TMS or brain tumor (n (%)) 2 (9.5)
PML or brain tumor (n (%)) 7 (33.3)
Tumefactive demyelination or brain tumor (n (%)) 8 (38.1)
Therapy at time of scan
Natalizumab (n (%)) 6 (28.6)
Steroids (n (%)) 6 (28.6)
Glatiramer acetate (n (%)) 2 (9.5)
No therapy (n (%)) 5 (23.8)
Fingolimod (n (%)) 1 (4.8)
Fingolimod + steroids (n (%)) 1 (4.8)
Interferon β-1a followed by dimethyl fumarate (n (%)) 1 (4.8)
ADEM indicates acute disseminated encephalomyelitis; MS, multiple sclerosis;
PML, progressive multifocal leukoencephalopathy; SD, standard deviation; TMS,
tumefactive multiple sclerosis.
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absence of tumor-specific therapy was defined to indicate a non-
neoplastic nature of the lesion.
Statistical Analysis
Ordinal and non-dichotomous variables are presented as
median with ranges. Nominal variables and non-dichotomous
variables are presented as mode (in percentage), while ratio vari-
ables are presented as geometric mean with added/subtracted stan-
dard deviation. FET-PET parameters of true neoplastic lesions and
tumefactive demyelinating lesions were compared using Mann-
Whitney U-test. According to the standard of reference, the area under
the ROC curve and the 95% confidence intervals were calculated,
fitted for SUVmax and TBRmax. P-values of less than 0.05 were
considered to indicate significance. All statistical analysis were
carried out using SPSS® version 22 (IBM, Armonk, NY).
RESULTS
Between January 2001 and December 2016, 21 patients were
included. Demographic data including reason for referral are
summarized in Table 1. The median interval between MR scan
and FET-PET scan was 13 ± 45.0 days. The most common loca-
tion of the culprit lesion was the supratentorial deep white matter
(6/21 patients, 28.6%), followed by the white matter of the frontal
lobes (5/21 patients, 23.8%) and temporal lobes (5/21 patients,
23.8%). The remainder of lesions was located in the white matter
of the parietal lobe, in the thalamus and in the infratentorial area.
Final diagnosis of lesions is given in Table 2. Nine patients
(42.9%) had true neoplastic lesions and 12 patients (57.1%) had
non-neoplastic tumefactive demyelinating lesions. Eleven patients
(52.3%) with previously diagnosed multiple sclerosis were under
MS-specific therapy. Seven thereof underwent biopsy, and histopa-
thology revealed tumefactive demyelinations in four patients, and
neoplastic tumors in the other three patients (glioblastoma, lym-
phoma). The age of patients with true neoplastic lesions and non-
neoplastic tumefactive demyelinating lesions was not different
(51.4 ± 10.0 years vs. 45.6 ± 17.7 years, respectively; P = 0.337).
MR imaging features of lesions are given in Table 3. The size
of tumors and TDL was comparable (P = 0.102). CSF circulation
impairment occurred in one patient with gliomatosis cerebri.
For the FET-PET scans, patients were injected with an aver-
age dose of 131.9 ± 4.6 MBq. FET-PET parameters of brain tumors
and TDL are given in Table 4. SUVmax and TBRmax were signifi-
cantly higher in brain tumors than in TDL. Tumors had a higher
TBRmax (3.53 ± 1.09 vs. 1.48 ± 0.31, respectively; P < 0.001) and
SUVmax (3.95 ± 1.59 vs. 1.86 ± 0.50, respectively; P < 0.001) than
tumefactive demyelinating lesions.
The dynamic FET uptake of TDL and neoplastic lesions is
shown in Figure 1. The receiver operating characteristic (ROC)
analysis revealed that a TBRmax threshold of 2.2 and a SUVmax
threshold of 2.5 are able to reliably differentiate tumors and
tumefactive demyelinations (area under the curve, 1.000 (confidence
interval, 1.000–1.000) and 0.958 (confidence interval, 0.000–1.000),
respectively). Figure 2 shows the distribution of TBRmax in TDL and
TABLE 2. Final Diagnosis of Lesions
Standard of reference
Histopathology (stereotactic biopsy) (n (%)) 6 (28.6)
Histopathology (surgical biopsy) (n (%)) 7 (33.3)
Clinical and imaging follow-up (n (%)) 8 (38.1)
Final diagnosis
Demyelination (n (%)) 12 (57.1)
Neoplastic tumor (n (%)) 9 (42.9)
Tumor type
Glioblastoma (n (%)) 5 (23.8)
Lymphoma (n (%)) 2 (9.5)
Oligodendroglioma (n (%)) 1 (4.8)
Gliomatosis cerebri (n (%)) 1 (4.8)
Tumor grade according to WHO
IV (n (%)) 5 (23.8)
III (n (%)) 2 (9.5)
Although listed in the WHO classification system and being considered high-grade
lesions, cerebral lymphomas are primarily characterized by their cell of origin and are
not assigned to a specific grade.
WHO indicates World Health Organization.
TABLE 3. MR Characteristics of Lesions
Neoplastic
Tumors
(n = 9)
Tumefactive
Demyelinations
(n = 12)
Volume on FLAIR
Mean ± SD (cm3) 17.4 ± 15.0 11.0 ± 13.1
Contrast enhancement
Yes (n (%)) 6 (66.7) 10 (83.3)
No (n (%)) 3 (33.3) 2 (16.7)
FLAIR borders
Well-defined (n (%)) 4 (44.4) 4 (33.3)
Ill-defined (n (%)) 5 (55.6) 8 (66.7)
Presence of diffusion restriction
Yes (n (%)) 4 (44.4) 5 (41.7)
No (n (%)) 5 (55.6) 7 (58.3)
Presence of perilesional edema
Yes (n (%)) 5 (55.6) 6 (50.0)
No (n (%)) 4 (44.4) 6 (50.0)
ADC signal
Bright (n (%)) 3 (33.3) 7 (58.3)
Mixed (n (%)) 4 (44.4) 5 (41.7)
Dark (n (%)) 2 (22.2) 0 (0.0)
ADC indicates apparent diffusion coefficient; FLAIR, fluid-attenuated inversion
recovery; SD, standard deviation.
TABLE 4. FET-PET Data of Lesions
Neoplastic
Tumors
(n = 9)
Tumefactive
Demyelinations
(n = 12)
SUVmax
Mean ± SD 3.95 ± 1.59 1.86 ± 0.50
TBRmax
Mean ± SD 3.53 ± 1.09 1.48 ± 0.31
Curve pattern
Wash-in (n (%)) 1 (11.1) 7 (58.3)
Plateau (n (%)) 0 (0.0) 4 (33.3)
Wash-in, thenwash-out (n (%)) 8 (88.9) 1 (8.3)
Sum of differences
Mean ± SD −0.08 ± 0.36 0.21 ± 0.16
SD indicates standard deviation; SUVmax, maximum standardized uptake value;
TBRmax, maximum tumefactive lesion-to-brain ratio.
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neoplastic lesions. Values ranged from 1.0–1.9 in TDL and 2.4–5.5 in
tumor lesions.
DISCUSSION
Because the discrimination of tumefactive demyelinating le-
sions and neoplastic lesions with MR is oftentimes challenging,
and misinterpretation might possibly have severe consequences,
the aim of our study was to investigate the use of non-invasive
FET-PET for this purpose. FET-PET scans are an established tool
for detection, observation and differentiation of supratentorial brain
tumors and for the estimation of prognosis in patients with
gliomas.23–25,31,35 Potential diagnostic benefits of FET-PET scans
for the differentiation of neoplastic lesions and TDL have yet not
been investigated systematically. Up to now, the only evidence
indicating a potential benefit of this imaging method is one single
case report.17
In our study, we observed significantly higher TBRmax and
SUVmax in brain tumors compared to TDL. As shown in Figure 2,
no overlap of TBRmax in TDL and neoplastic lesions was observed,
rendering this parameter highly accurate. ROC analysis revealed an
optimal cut-off at a TBRmax of 2.2. These findings are consistent
with findings by Rapp et al. who established a similar threshold
for discriminating low-grade tumors and high-grade tumors.23 In
our cohort, there were no low-grade tumors, which is likely due to
the inclusion criteria. Apparently, high-grade tumors are more likely
to meet the clinical presentation and radiological criteria of TDL
than low-grade tumors, owing to their comparably fast growth and
invasive behavior. Typical MR features of high-grade tumors are
e.g. contrast enhancement and presence of cystic/necrotic areas.
The spread of TBRmax values of TDLwas smaller compared to neo-
plastic lesions, probably reflecting a larger metabolic heterogeneity
among different types of tumors. Neoplasms in our cohort consisted
of glioblastoma, oligodendroglioma, gliomatosis cerebri as well
as lymphoma.
The SUVmax of high-grade brain tumors in our cohort are
comparable with the literature.24 Also this parameter yielded a high
discriminatory power in the ROC analysis, with an optimal cut-off
obtained at 2.5. As shown by previous studies, late TAC kinetics
(20–40 min) are important for the discrimination of high-grade tu-
mors and inflammatory lesions.24,36 Since our study was conducted
retrospectively in patients who underwent a clinical PETwith lim-
ited acquisition time, data on the time to peak of the TAC cannot
be derived for every lesion, and is therefore not discussed. Our
TAC analysis shows that the SUVmax was significantly different in
tumors and demyelinating lesions at every PET frame. In accor-
dance with pertinent literature, the typical TAC pattern in neoplastic
lesions in our cohort was a wash-in, followed by a wash-out, which
was found in 89%.24,25 For TDL, we could not detect a specific
TAC pattern. Only one single TDL displayed the aforementioned
wash-out pattern, which is frequently observed in high-grade neo-
plastic lesions. Hence, presence of a wash-out pattern might be use-
ful for the differentiation of (high-grade) tumors and TDL using
dynamic FET-PET. The exact mechanisms of FET wash-out in
high-grade brain tumors are not completely understood, but proba-
bly rely on a combination of passive efflux and active transport. No-
tably, our study does not provide information on the differentiation
of TDL from low-grade tumors.
Histopathological examination is the accepted standard of
reference to distinguish neoplastic lesions and TDL, but is not always
practicable, owing to invasiveness, potential complications and
limitations due to the anatomical location of lesions. Furthermore,
misinterpretation of TDL as neoplastic lesions due to a hypercellular
pattern, atypical reactive astrocytosis and mitotic figures are possi-
ble.37,38 In the trial of Lucchinetti et al., misdiagnosis occured in
approximately 30% of biopsies.1
Although TDL might be an overall rare finding in MR scans
of patients with demyelinating disease, a reliable differentiation
from true neoplastic lesions is important in order to allow for ap-
propriate therapy. As shown in Figure 3 and Figure 4, MR char-
acteristics of tumefactive demyelinations and neoplastic lesions
may appear similar and are oftentimes not specific for either en-
tity. Several contrast enhancement patterns have been described
for TDL, such as homogenous, heterogeneous, nodular, or closed vs.
open rings pointing towards gray matter.1,9,39 In our cohort, presence
or absence of MR contrast enhancement and/or perilesional edema
could not distinguish TDL from neoplastic lesions. This is not only
FIGURE 2. Boxplot of TBRmax of tumefactive demyelinations
and neoplastic tumors. The horizontal borders correspond
to the median and the 25th and 75th percentile, respectively.
Whiskers indicate the minimal and maximal value.
FIGURE 1. Dynamic 18F-FET uptake of lesions. The graph
shows themaximum standardized uptake value (SUVmax) of
tumefactive demyelinations and neoplastic tumors.
Mann-Whitney U-test revealed significant differences at all
time points (22.5 min, P = 0.004, 27.5 min, P = 0.004,
32.5 min, P = 0.001, 37.5 min, P = 0.006).
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a result of our selection criteria, which basically revert to MR scans
being equivocal for the discrimination of both entities, but these
findings are also reflected by the currently ambiguous definition
of TMS lesions. FLAIR borders and volume of lesions were also
not helpful for differentiating demyelinating lesions and neoplastic
lesions in our cohort. However, as described by Floeth et al., lesion
borders on FLAIR-weighted images might still harbor prognostic
value for low-grade gliomas.31 Fliss et al. showed in a hybrid
PET/MR study, that FET-PETand perfusion-weighted MR in fact
yield different information in patients with brain tumors, with
larger tumor volumes obtained with FET-PET than with the regional
cerebral blood volume derived from MR.33 However, their study did
not contain demyelinating lesions, and our study does not contain
perfusion MR imaging. Hence, possible conclusions are limited.
Nevertheless, multimodal hybrid imaging, such as PET/MR, might
provide diagnostic benefits compared to sequential single modality
imaging in patients with neoplastic lesions, since the correlation with
histopathological malignancy indices is probably more consistent.40
Also the ADC signal could not discriminate demyelinating
lesions and neoplastic lesions in our cohort. In our cohort and cor-
responding to pertinent literature, TDL are consistently of bright or
intermediate signal intensity on ADC, but not dark. This might be
related to the presence of vasogenic edema.MS lesions are alsowell
known to change their ADC signal during disease progression.41–43
Overall, there was a significant overlap of the ADC signal of TDL
and true neoplastic lesions in our cohort.
Altogether, our results show that TDLmight be distinguished
from brain tumors using FET-PET, if conventional MR imaging is
not able to answer this question.3,44 Both the misinterpretation of
a neoplastic lesion as demyelinating disease and vice versa might
expose the patient to unnecessary risks, be it delayed surgery or che-
moradiation treatment in the first case, or unnecessary treatment in
the latter one.45 Also an initial high-dose steroid therapy, which is
occasionally given to reduce the perilesional edema in neoplastic
lesions as well as for immunosuppression in MS patients, may
eventually lead to an exacerbation of neoplastic lesions.46,47
FIGURE 4. Glioblastoma multiforme in an MS patient. The new appearing lesion in the left-sided insula (arrow) shows
some contrast enhancement, predominantly at the rim on the T1-weighted MR image (A). The lesion (arrow) is hyperintense
on the FLAIR-weighted MR image (B). In the periphery of the lesion, confluent hyperintense areas (arrowheads) are seen.
Focal demyelinations (small arrows) are seen in the internal capsule and subependymal area adjacent to the frontal horn aswell
as in the parahippocampal gyrus and subependymal area adjacent to the trigone on the right side. FET-PET (C) co-registered
with the T1-weighted MR image reveals high uptake of the lesion (arrow, SUVmax 6.0, TBRmax 5.2) and another small focus
posteriorly (arrowhead).
FIGURE 3. Tumefactive demyelinating lesion in a patient with demyelinating disease. The new appearing lesion in the
left-sided frontal lobe (arrow) shows patchy contrast enhancement (arrowheads) at the rim on the T1-weightedMR image (A).
The lesion (arrow) is hyperintense on the FLAIR-weighted MR image (B). Other demyelinations are seen throughout the
brain, e.g. in subependymal location adjacent to the right-sided frontal horn (short arrow). FET-PET (C) co-registered with
the T1-weighted MR image reveals very low uptake of the lesion (arrow, SUVmax 1.9, TBRmax 1.2), with a completely
FET-negative center.
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Modern MS therapy is known to modulate the immune system in
various and mainly suppressive ways. On the other hand, a func-
tioning immune system is important for the response to tumors,
and immunosuppression was shown to affect the prognosis in
glioblastoma patients.48,49
We acknowledge several limitations of our study. First, we
only included patients where the MR scan was equivocal, and can
thus not comment on the diagnostic accuracy of MR vs. FET-PET
imaging in a more general population of patients with demyelinat-
ing disease. The diagnostic accuracy of MR in our cohort is biased
owing to these selective criteria, however, the diagnostic perfor-
mance of MR was also not the thrust of our study. Notably, particu-
larly patients with equivocal MR scans would be the cohort with
potential benefits from FET-PET imaging, considering also the radi-
ation burden from FET-PET. Second, FET-PET scans were acquired
on different scanners. However, PET parameters such as SUVmax
are a reproducible and standardized measure and all FET-PET pro-
cedures in our cohort followed an institutionally standardized proto-
col. For the TAC, we used 20–40 min. Other authors used various
acquisition frames between 0 and 50min for FET-PET studies, with
10–30 min being most commonly applied. In order to recognize
basic radiotracer kinetic patterns as in our study, the 20–40 min
and 10–30 min approaches are considered comparable. Recently,
the dynamic 20–40 min acquisition has gained more atten-
tion.36,50,51 Third, owing to the low number of subjects, we could
not provide a subanalysis of separate TDD. However, the clinical
and radiological presentation of different TDD is often similar. The
sample size was rather small, although the inclusion period of our
study covered more than a decade at a major tertiary care center. This
is mainly owing to the infrequent nature of the analyzed pathology.
Thus, future multicenter studies are desired. The small sample size
might have affected the ROC calculation. Nevertheless, significantly
different TBRmax and SUVmax between TDL and brain tumors were
found. In addition, there is a lack of similar reports in the literature,
which precludes a comparison of our results with data published
by peers.
In conclusion, we found that FET-PET parameters TBRmax
(cut-off 2.2) and SUVmax (cut-off 2.5) are able to distinguish
tumefactive demyelinations from true neoplastic lesions. Our find-
ings may offer benefits for patients with known or suspected demy-
elinating disease and equivocal MR imaging results with regard to
tumefactive lesions. Further prospective studies should be conducted
in a multi-center setting, owing to the comparably low incidence of
tumefactive lesions in patients with demyelinating disease.
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